Skip to main content
SpringerLink
Log in

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ryken TC, Aygun N, Morris J, Schweizer M, Nair R, Spracklen C, Kalkanis SN, Olson JJ (2014) The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline. J Neurooncol 118:435–460

    Article  CAS  PubMed  Google Scholar 

  2. Heiss WD (2014) Clinical impact of amino acid PET in gliomas. J Nucl Med. doi:10.2967/jnumed.114.142661

    Google Scholar 

  3. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al (2006) O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294

    Article  CAS  PubMed  Google Scholar 

  4. Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M et al (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505–511

    Article  PubMed  Google Scholar 

  5. Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al (2006) Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393–403

    PubMed  Google Scholar 

  6. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI et al (2012) Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 53:1367–1374

    Article  CAS  PubMed  Google Scholar 

  7. Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K et al (2012) Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-l-Tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057

    Article  CAS  PubMed  Google Scholar 

  8. Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC et al (2006) Serial O-(2-[(18)F]fluoroethyl)-l-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imag 33:792–800

    Article  Google Scholar 

  9. Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M et al (2005) O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imag 32:1018–1025

    Article  CAS  Google Scholar 

  10. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH et al (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imag 40:22–33

    Article  CAS  Google Scholar 

  11. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H et al (2011) O-(2-18F-fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856–864

    Article  CAS  PubMed  Google Scholar 

  12. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR et al (2014) Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-oncology 16:603–609

    Article  PubMed  Google Scholar 

  13. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, Muller HW et al (2004) Comparison of O-(2-18F-fluoroethyl)-l-tyrosine PET and 3-123I-iodo-alpha-methyl-l-tyrosine SPECT in brain tumors. J Nucl Med 45:374–381

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Leo-Brandt-Str. 5, 52425, Jülich, Germany

    Karl-Josef Langen & Norbert Galldiks

  2. Department of Nuclear Medicine, University of Aachen, Aachen, Germany

    Karl-Josef Langen

  3. Department of Neurosurgery, University of Munich, Munich, Germany

    Jörg C. Tonn

  4. Department of Neurology, University Hospital Zurich, Zurich, Switzerland

    Michael Weller

  5. Department of Neurology, University of Cologne, Cologne, Germany

    Norbert Galldiks

Authors
  1. Karl-Josef Langen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg C. Tonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norbert Galldiks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl-Josef Langen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langen, KJ., Tonn, J.C., Weller, M. et al. Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]. J Neurooncol 120, 665–666 (2014). https://doi.org/10.1007/s11060-014-1594-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1594-z

Keywords

Search

Navigation